153 results on '"Largaespada, David A."'
Search Results
2. An insertional mutagenesis screen identifies genes that cooperate with Mll-AF9 in a murine leukemogenesis model
3. A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene
4. RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia
5. Repressible transgenic model of NRAS oncogene–driven mast cell disease in the mouse
6. Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system
7. NRASG12V-Mediated Self-Renewal Signaling in Self-Renewing AML Stem Cells.
8. What gene have I ID'ed?
9. Immunoproteasome Inhibition to Target AML with Activated RAS Pathways
10. Single-Cell Analysis Reveals Molecular Mechanisms of NRAS-Mediated Leukemia Stem Cell Self-Renewal in a Murine Model of AML
11. Forward Genetic Screen Implicates Drivers of Leukemic Progression in a Novel Model of Trp53 R270Hmyelodysplastic Syndrome
12. Single-Cell Transcriptional Profiling of Acute Myeloid Leukemia Identifies Prognostic Transcriptional Profiles at Diagnosis
13. Ras Effector Pathways Differentially Support Proliferation and Survival of Acute Myeloid Leukemia
14. NRAS G12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia
15. Ras-Pathway Inhibition With Targeted Therapies Abrogates Self-Renewal In Acute Myelogenous Leukemia
16. Retroviral Insertional Mutagenesis In Egr1+/- mice, Haploinsufficient For a Human Del(5q) Myeloid Leukemia Gene, Develop Myeloid Neoplasms With Proviral Insertions In Genes Syntenic To Human 5q
17. Cellular Intrinsic Mechanism Affecting The Outcome Of AML Treatment With Ara-C In a Syngeneic Mouse Model
18. Activated NRAS Mediates Self-Renewal Capacity in AML by Facilitating the Mll/AF9-Specified Gene Expression Signature
19. Delineating Critical Effectors of Remission Induction in a Mouse Model of AML
20. Assessing Potential Genotoxicity of Sleeping Beauty Transposition Events in T-Cell Immunotherapy by Supercomputer-Based High Throughput Profiling,
21. Mechanisms of Relapse Following Targeted Therapy in An NRASG12V and Mll-AF9 Driven Mouse Model of AML
22. RNA-Sequencing of the Transcriptome of Ara-C Resistant Murine AML Cell Lines Identifies Potential Drug Targets
23. Oncogene Withdrawal Selectively Alters Phosphoprotein States and Shifts Differentiation Status In Myeloid Leukemia Subpopulations
24. A Screen for Drugs Showing Specific Co-Resistance or Hyper-Sensitivity Upon the Acquisition of Ara-C Resistance In AML
25. An Insertional Mutagenesis Screen for Genes That Cooperate with Mll-AF9 in Leukemogenesis.
26. Combinations of Kinase Inhibitors May Be An Effective Therapeutic Strategy for Acute Myeloid Leukemia (AML) with MLL-AF9 Expression.
27. A Murine AML Model for the Development of Resistance to NRAS(G12V) Oncogene Repression and/or Ara-C Treatment in Vivo
28. A Novel Microarray Gene Expression Analysis of Murine AML Cell Lines Provides Clues to the Development of Drug Resistance to Ara-C
29. Novel Mll-AF9 Cooperating Genes Identified in a Leukemogenesis Screen Using Retroviral Mutagenesis.
30. Bcl11a Causes p21Cip1 Down-Regulation and Transplantable Leukemia in Nf1-Deficient Mice.
31. Continued Expression of the NRAS(G12V) Oncogene Is Required for the Maintenance of Acute Myeloid Leukemia Induced in Cooperation with MLL-AF9.
32. Influence of Maternal Folic Acid Supplementation on Hematopoietic Factors in Offspring.
33. Genetic Mechanisms of Cytarabine Resistance in Leukemia: Cell Culture and Mouse Transplantation Models.
34. A Screen for Mll-AF9 Cooperating Mutations in Leukemogenesis Using MLV-Based Mutagenesis.
35. Bcl11a Causes Leukemia/Lymphoma in Cooperation with Nf1 Inactivation.
36. β common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice
37. Genetic Dissection of Leukemogenesis-Related Genes/Pathways Cooperating with AML1/ETO.
38. In Vitro Derivation of ARA-C Resistant BXH-2 AML Cell Lines: Association of RAS/MAPK and P53-Regulated Pathways with Chemoresistance.
39. Genetic Dissection of Cooperating Mutations in BXH-2 Acute Myeloid Leukemia with and without Nf1 Gene Mutation.
40. Cooperative Pathways to Acute Myeloid Leukemia Include the Combining of Transcription Factor Alterations: PML-RARα Cooperates with SOX4.
41. Expression Signature of Therapy Resistant AML: Use of In Vitro Selected Ara-C Resistant BXH-2 Strain AML Cell Lines.
42. In Vivo Regulatable Mouse Models of NRAS(V12)-Driven Acute Systemic Mastocytosis and Acute Myeloid Leukemia.
43. An insertional mutagenesis screen identifies genes that cooperate with Mll-AF9in a murine leukemogenesis model
44. RASoncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia
45. A retroviral mutagenesis screen reveals strong cooperation between Bcl11aoverexpression and loss of the Nf1tumor suppressor gene
46. β common receptor inactivation attenuates myeloproliferative disease in Nf1mutant mice
47. Repressible transgenic model of NRASoncogene–driven mast cell disease in the mouse
48. Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beautytransposon system
49. Activated NRASMediates Self-Renewal Capacity in AML by Facilitating the Mll/AF9-Specified Gene Expression Signature
50. Assessing Potential Genotoxicity of Sleeping BeautyTransposition Events in T-Cell Immunotherapy by Supercomputer-Based High Throughput Profiling,
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.